Filing Details
- Accession Number:
- 0001209191-23-002976
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-01-11 16:07:13
- Reporting Period:
- 2023-01-10
- Accepted Time:
- 2023-01-11 16:07:13
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1434316 | Fate Therapeutics Inc | FATE | Biological Products, (No Disgnostic Substances) (2836) | 651311552 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1868719 | Mark Plavsic | C/O Fate Therapeutics, Inc. 12278 Scripps Summit Drive San Diego CA 92131 | Chief Technical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2023-01-10 | 3,418 | $5.24 | 123,705 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct |
Footnotes
- Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 8,325 shares of Common Stock underlying restricted stock units granted to the Reporting Person on January 25, 2022. This sale was made pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
- Represents the weighted average sale price of the shares sold from $5.12 to $5.37 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of he Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.